<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01914757</url>
  </required_header>
  <id_info>
    <org_study_id>D3250C00018</org_study_id>
    <nct_id>NCT01914757</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist</brief_title>
  <official_title>A Multicentre, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Asthmatic Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist (CALIMA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Benralizumab reduces the exacerbation rate
      in patients with a history of asthma exacerbations and uncontrolled asthma receiving ICS-LABA
      with or without oral corticosteroids and additional asthma controllers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils &gt;=300/uL</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 56.</time_frame>
    <description>The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils &lt;300/uL</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 56.</time_frame>
    <description>The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils &gt;=300/uL</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 56.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils &lt;300/uL</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 56.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils &gt;=300/uL</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 56.</time_frame>
    <description>Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma). Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils &lt;300/uL</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 56.</time_frame>
    <description>Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma). Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Asthma Rescue Medication Use</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 56.</time_frame>
    <description>Change from Baseline to Week 56 in number of Rescue medication use (puffs/day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Home Lung Function Assessments Based on PEF</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 56.</time_frame>
    <description>Change from Baseline to Week 56 in Home lung function (morning and evening Peak expiratory flow [PEF])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Nights With Awakening Due to Asthma</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 56.</time_frame>
    <description>Change from Baseline to Week 56 on Proportion of Nights with awakening due to asthma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils &gt;=300/uL</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 56.</time_frame>
    <description>ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of &lt;=0.75 indicates well-controlled asthma, scores between 0.75 to &lt;=1.5 indicate partly controlled asthma, and &gt;1.5 indicates not well controlled asthma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils &lt;300/uL</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 56.</time_frame>
    <description>ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of &lt;=0.75 indicates well-controlled asthma, scores between 0.75 to &lt;=1.5 indicate partly controlled asthma, and &gt;1.5 indicates not well controlled asthma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With &gt;=1 Asthma Exacerbation</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Asthma Exacerbation</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Asthma Exacerbation Resulting Emergency Room Visits and Hospitalizations</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 56.</time_frame>
    <description>Annual rate of asthma exacerbations that are associated with an emergency room visit or a hospitalization (adjudicated)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Benralizumab</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 16, Week 24, Week 32, Week 40, Week 48, Week 56, Week 60</time_frame>
    <description>Mean PK Concentration at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of Benralizumab</measure>
    <time_frame>Pre-treatment until end of follow-up</time_frame>
    <description>Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at &gt;=2 post-baseline assessments (with &gt;=16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive is defined as having at least one post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of Exposure</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 56</time_frame>
    <description>Extent of exposure is defined as the duration of treatment in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 56 in AQLQ(S)+12</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 56</time_frame>
    <description>AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of &gt;=0.5 are considered clinically meaningful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 56 in EQ-5D-5L VAS</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 56</time_frame>
    <description>EQ-5D-5L VAS is to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Work Productivity Loss Due to Asthma</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 56</time_frame>
    <description>WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked. This is only applicable to patients who were employed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Productivity Loss Due to Asthma in Classroom</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 56</time_frame>
    <description>WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Classroom productivity loss is derived by sum of percentage of missed classes due to asthma and product of percentage of actual hours attending classes times degree of asthma affecting classroom productivity. Percentage of missed classes due to asthma is calculated by number of hours missed classes due to asthma divided by total number of hours missed classes plus number of hours actually attending classes. This is only applicable for patients who took classes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Utilized Health Care Resources</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and Clinician Assessment of Response to Treatment</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 56</time_frame>
    <description>CGIC (clinician global impression of change), and PGIC (patient global impression of change) are overall evaluation of response to treatment, conducted separately by investigator and patient using a 7-point rating scale, ranging from 1 (Very much Improved), to 7 (Very much Worse). This endpoint was added after the second protocol amendment, thus not all patients had data to be analyzed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2508</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Benralizumab 30 mg q.4 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benralizumab administered subcutaneously every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benralizumab 30 mg q.8 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benralizumab administered subcutaneously every 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Benralizumab</intervention_name>
    <description>Benralizumab subcutaneously on study week 0 until study week 52 inclusive.</description>
    <arm_group_label>Benralizumab 30 mg q.4 weeks</arm_group_label>
    <arm_group_label>Benralizumab 30 mg q.8 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo subcutaneously on study week 0 until study week 52 inclusive.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of informed consent prior to any study specific procedures

          2. Female and male aged 12 to 75 years, inclusively, at the time of Visit 1

          3. History of physician-diagnosed asthma requiring treatment with medium-to-high dose ICS
             (&gt;250µg fluticasone dry powder formulation equivalents total daily dose) and a LABA,
             for at least 12 months prior to Visit 1.

          4. Documented treatment with ICS and LABA for at least 3 months prior to Visit 1 with or
             without oral corticosteroids and additional asthma controllers. The ICS and LABA can
             be parts of a combination product or given by separate inhalers. The ICS dose must be
             greater than or equal to 500 μg/day fluticasone propionate dry powder formulation or
             equivalent daily. For ICS/LABA combination preparations, the mid-strength approved
             maintenance dose in the local country will meet this ICS criterion.

        Exclusion criteria:

          1. Clinically important pulmonary disease other than asthma (e.g. active lung infection,
             COPD, bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome
             associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary
             ciliary dyskinesia) or ever been diagnosed with pulmonary or systemic disease, other
             than asthma, that are associated with elevated peripheral eosinophil counts (e.g.
             allergic bronchopulmonary aspergillosis/mycosis, Churg- Strauss syndrome,
             hypereosinophilic syndrome)

          2. Any disorder, including, but not limited to, cardiovascular, gastrointestinal,
             hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic,
             haematological, psychiatric, or major physical impairment that is not stable in the
             opinion of the Investigator and could:

               -  Affect the safety of the patient throughout the study

               -  Influence the findings of the studies or their interpretations

               -  Impede the patient's ability to complete the entire duration of study

          3. Acute upper or lower respiratory infections requiring antibiotics or antiviral
             medication within 30 days prior to the date informed consent is obtained or during the
             screening/run-in period

          4. Any clinically significant abnormal findings in physical examination, vital signs,
             haematology, clinical chemistry, or urinalysis during screening/run-in period, which
             in the opinion of the Investigator, may put the patient at risk because of his/her
             participation in the study, or may influence the results of the study, or the
             patient's ability to complete entire duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Fitzgerald, MD, PhD, Professor of Medicine</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Lung Centre, Gordon and Leslie Diamond Health Care Centre, Vancouver Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Andalusia</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Flagstaff</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alhambra</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palmdale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Redondo Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rolling Hills Estate</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Westminister</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woodland</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Celebration</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lehigh Acres</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Virginia Gardens</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Smyrna</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eagle</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shiloh</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Mitchell</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vagas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Union</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jefferson Hills</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indian Land</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boerne</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Midvale</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad Autónoma de Bs. As.</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Concepción del Uruguay</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Corrientes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Córdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Florida</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Godoy Cruz</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mar del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ranelagh</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sherwood Park</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St Charles Borromee</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Concepcion</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quillota</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Talcahuano</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valparaiso</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Viña del Mar</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bamberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt/Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Geesthacht</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gelsenkirchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Herford</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Neu-Isenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rüdersdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Witten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Asahi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiyoda-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Himeji-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hiroshima-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Itabashi-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kagoshima-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kishiwada-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kobe-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kokubunji-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsue-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minato-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mizunami-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Niigata-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Obihiro-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oita-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ota-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sagamihara-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sakai-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sakaide-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Setagaya-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shibuya-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sumida-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takamatsu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toshima-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tsukubo-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iloilo City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lipa City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aleksandrów Łódzki</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bielsko Biala</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bystra Śląska</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gorzów Wlkp</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Karczew</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koszalin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lubin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrów Wielkopolski</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruda Slaska</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rzeszów</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Skierniewice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tarnów</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toruń</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trzebnica</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wieluń</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zabrze</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łęczna</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Żnin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bragadiru</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Constanta</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Deva</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Luleå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chernivtsi</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lutsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mykolayiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uzhgorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinnytsya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporizhzhia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporozhye</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Sweden</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1823&amp;filename=d3250c00018_Revised_CSP_CALIMA..pdf</url>
    <description>D3250C00018CSP3redacted</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2013</study_first_submitted>
  <study_first_submitted_qc>July 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2013</study_first_posted>
  <results_first_submitted>September 8, 2016</results_first_submitted>
  <results_first_submitted_qc>November 30, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 25, 2017</results_first_posted>
  <last_update_submitted>November 30, 2016</last_update_submitted>
  <last_update_submitted_qc>November 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases</keyword>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>2505 participants signed informed consent, 2181 entered screening/run-in period, 1306 participants were randomised to receive treatment with benralizumab 30 mg Q4W, Q8W, or placebo. Of the 1306 patients randomised, all (100.0%) received treatment with study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Benralizumab 30 mg q.4 Weeks</title>
          <description>Benralizumab administered subcutaneously every 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Benralizumab 30 mg q.8 Weeks</title>
          <description>Benralizumab administered subcutaneously every 8 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo administered subcutaneously</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="425"/>
                <participants group_id="P2" count="441"/>
                <participants group_id="P3" count="440"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="389"/>
                <participants group_id="P2" count="390"/>
                <participants group_id="P3" count="402"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Severe non-compliance to protocol</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study specific withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Eligibility criteria not fulfilled</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Benralizumab 30 mg q.4 Weeks</title>
          <description>Benralizumab administered subcutaneously every 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Benralizumab 30 mg q.8 Weeks</title>
          <description>Benralizumab administered subcutaneously every 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo administered subcutaneously</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="425"/>
            <count group_id="B2" value="441"/>
            <count group_id="B3" value="440"/>
            <count group_id="B4" value="1306"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.0" spread="13.6"/>
                    <measurement group_id="B2" value="49" spread="14.3"/>
                    <measurement group_id="B3" value="48.8" spread="15.1"/>
                    <measurement group_id="B4" value="49.2" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="270"/>
                    <measurement group_id="B2" value="273"/>
                    <measurement group_id="B3" value="264"/>
                    <measurement group_id="B4" value="807"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="176"/>
                    <measurement group_id="B4" value="499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils &gt;=300/uL</title>
        <description>The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF.</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 56.</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils &gt;=300/uL</title>
          <description>The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF.</description>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS.</population>
          <units>Events/year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.48" upper_limit="0.74"/>
                    <measurement group_id="O2" value="0.66" lower_limit="0.54" upper_limit="0.82"/>
                    <measurement group_id="O3" value="0.93" lower_limit="0.77" upper_limit="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Negative Binomial</method>
            <method_desc>Model includes covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>Negative Binomial</method>
            <method_desc>Model includes covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids.</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils &lt;300/uL</title>
        <description>The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF.</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 56.</time_frame>
        <population>Full analysis set, Baseline eosinophils &lt;300/uL, High-dose ICS.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils &lt;300/uL</title>
          <description>The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF.</description>
          <population>Full analysis set, Baseline eosinophils &lt;300/uL, High-dose ICS.</population>
          <units>Events/year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" lower_limit="0.59" upper_limit="1.02"/>
                    <measurement group_id="O2" value="0.73" lower_limit="0.55" upper_limit="0.95"/>
                    <measurement group_id="O3" value="1.21" lower_limit="0.96" upper_limit="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>Negative Binomial</method>
            <method_desc>Model includes covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Negative Binomial</method>
            <method_desc>Model includes covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids.</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils &gt;=300/uL</title>
        <time_frame>Immediately following the first administration of study drug through Study Week 56.</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils &gt;=300/uL</title>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="211"/>
                <count group_id="O3" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="0.469"/>
                    <measurement group_id="O2" value="0.332" spread="0.518"/>
                    <measurement group_id="O3" value="0.206" spread="0.471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline pre-BD FEV1, region, use of OCS, visit, and treatment by visit</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.125</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.037</ci_lower_limit>
            <ci_upper_limit>0.213</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline pre-BD FEV1, region, use of OCS, visit, and treatment by visit</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.116</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.028</ci_lower_limit>
            <ci_upper_limit>0.204</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils &lt;300/uL</title>
        <time_frame>Immediately following the first administration of study drug through Study Week 56.</time_frame>
        <population>Full analysis set, Baseline eosinophils &lt;300/uL, High-dose ICS</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils &lt;300/uL</title>
          <population>Full analysis set, Baseline eosinophils &lt;300/uL, High-dose ICS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.221" spread="0.441"/>
                    <measurement group_id="O2" value="0.164" spread="0.358"/>
                    <measurement group_id="O3" value="0.135" spread="0.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.268</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline pre-BD FEV1, region, use of OCS, visit, and treatment by visit</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.064</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.049</ci_lower_limit>
            <ci_upper_limit>0.176</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.786</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline pre-BD FEV1, region, use of OCS, visit, and treatment by visit</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.015</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.127</ci_lower_limit>
            <ci_upper_limit>0.096</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils &gt;=300/uL</title>
        <description>Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma). Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 56.</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils &gt;=300/uL</title>
          <description>Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma). Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.</description>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.33" spread="1.23"/>
                    <measurement group_id="O2" value="-1.4" spread="1.17"/>
                    <measurement group_id="O3" value="-1.2" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.224</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline Asthma symptom score, region, use of OCS, visit, and visit by treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.32</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline Asthma symptom score, region, use of OCS, visit, and visit by treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.43</ci_lower_limit>
            <ci_upper_limit>-0.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils &lt;300/uL</title>
        <description>Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma). Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 56.</time_frame>
        <population>Full analysis set, Baseline eosinophils &lt;300/uL, High-dose ICS</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils &lt;300/uL</title>
          <description>Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma). Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.</description>
          <population>Full analysis set, Baseline eosinophils &lt;300/uL, High-dose ICS</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.05" spread="1.14"/>
                    <measurement group_id="O2" value="-0.95" spread="1.13"/>
                    <measurement group_id="O3" value="-0.88" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.287</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline Asthma symptom score, region, use of OCS, visit, and visit by treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.966</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline Asthma symptom score, region, use of OCS, visit, and visit by treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Asthma Rescue Medication Use</title>
        <description>Change from Baseline to Week 56 in number of Rescue medication use (puffs/day)</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 56.</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Asthma Rescue Medication Use</title>
          <description>Change from Baseline to Week 56 in number of Rescue medication use (puffs/day)</description>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
          <units>Puffs per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="3.64"/>
                    <measurement group_id="O2" value="-2.92" spread="3.60"/>
                    <measurement group_id="O3" value="-2.65" spread="9.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.603</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline Asthma rescue medication use, region, use of OCS, visit, and visit by treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.58</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.209</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline Asthma medication use, region, use of OCS, visit, and visit by treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.29</ci_lower_limit>
            <ci_upper_limit>0.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Home Lung Function Assessments Based on PEF</title>
        <description>Change from Baseline to Week 56 in Home lung function (morning and evening Peak expiratory flow [PEF])</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 56.</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Home Lung Function Assessments Based on PEF</title>
          <description>Change from Baseline to Week 56 in Home lung function (morning and evening Peak expiratory flow [PEF])</description>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 56, Morning (n=194, 193, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.745" spread="78.534"/>
                    <measurement group_id="O2" value="43.375" spread="91.865"/>
                    <measurement group_id="O3" value="23.961" spread="71.509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 56, Evening (n=194, 192, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.142" spread="75.489"/>
                    <measurement group_id="O2" value="39.270" spread="89.772"/>
                    <measurement group_id="O3" value="15.448" spread="78.341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Morning PEF Change from Baseline to Week 56</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline morning PEF, region, use of OCS, visit, and visit by treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>15.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.59</ci_lower_limit>
            <ci_upper_limit>30.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Morning PEF Change from Baseline to Week 56</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline morning PEF, region, use of OCS, visit, and visit by treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>15.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>29.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Evening PEF Change from Baseline to Week 56</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline evening PEF, region, use of OCS, visit, and visit by treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>17.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.07</ci_lower_limit>
            <ci_upper_limit>32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Evening PEF Change from Baseline to Week 56</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline evening PEF, region, use of OCS, visit, and visit by treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>21.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.65</ci_lower_limit>
            <ci_upper_limit>35.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Nights With Awakening Due to Asthma</title>
        <description>Change from Baseline to Week 56 on Proportion of Nights with awakening due to asthma</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 56.</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Nights With Awakening Due to Asthma</title>
          <description>Change from Baseline to Week 56 on Proportion of Nights with awakening due to asthma</description>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
          <units>Proportion of nights</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.373" spread="0.388"/>
                    <measurement group_id="O2" value="-0.431" spread="0.4"/>
                    <measurement group_id="O3" value="-0.372" spread="0.405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline prop of nights with nocturnal wakening, region, use of OCS, visit, and visit by treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.146</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline prop of nights with nocturnal wakening, region, use of OCS, visit, and visit by treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils &gt;=300/uL</title>
        <description>ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of &lt;=0.75 indicates well-controlled asthma, scores between 0.75 to &lt;=1.5 indicate partly controlled asthma, and &gt;1.5 indicates not well controlled asthma.</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 56.</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils &gt;=300/uL</title>
          <description>ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of &lt;=0.75 indicates well-controlled asthma, scores between 0.75 to &lt;=1.5 indicate partly controlled asthma, and &gt;1.5 indicates not well controlled asthma.</description>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="1.13"/>
                    <measurement group_id="O2" value="-1.49" spread="1.13"/>
                    <measurement group_id="O3" value="-1.21" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.043</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline ACQ-6 score, region, use of OCS, visit, and visit by treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline ACQ-6 score, region, use of OCS, visit, and visit by treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils &lt;300/uL</title>
        <description>ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of &lt;=0.75 indicates well-controlled asthma, scores between 0.75 to &lt;=1.5 indicate partly controlled asthma, and &gt;1.5 indicates not well controlled asthma.</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 56.</time_frame>
        <population>Full analysis set, Baseline eosinophils &lt;300/uL, High-dose ICS</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils &lt;300/uL</title>
          <description>ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of &lt;=0.75 indicates well-controlled asthma, scores between 0.75 to &lt;=1.5 indicate partly controlled asthma, and &gt;1.5 indicates not well controlled asthma.</description>
          <population>Full analysis set, Baseline eosinophils &lt;300/uL, High-dose ICS</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" spread="1.16"/>
                    <measurement group_id="O2" value="-1.06" spread="1.02"/>
                    <measurement group_id="O3" value="-0.83" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.078</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline ACQ-6 score, region, use of OCS, visit, and visit by treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.51</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.449</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline ACQ-6 score, region, use of OCS, visit, and visit by treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With &gt;=1 Asthma Exacerbation</title>
        <time_frame>Immediately following the first administration of study drug through Study Week 56</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With &gt;=1 Asthma Exacerbation</title>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Proportion of patients with &gt;=1 asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlling for region, number of exacerbations in the previous year, use of OCS</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>0.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Proportion of patients with &gt;=1 asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlling for region, number of exacerbations in the previous year, use of OCS</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Asthma Exacerbation</title>
        <time_frame>Immediately following the first administration of study drug through Study Week 56</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Asthma Exacerbation</title>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Time to first Exacerbation</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model includes treatment, region, number of exacerbations in the previous year, use of OCS</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Time to first asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model includes treatment, region, number of exacerbations in the previous year, use of OCS</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Asthma Exacerbation Resulting Emergency Room Visits and Hospitalizations</title>
        <description>Annual rate of asthma exacerbations that are associated with an emergency room visit or a hospitalization (adjudicated)</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 56.</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Asthma Exacerbation Resulting Emergency Room Visits and Hospitalizations</title>
          <description>Annual rate of asthma exacerbations that are associated with an emergency room visit or a hospitalization (adjudicated)</description>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
          <units>Events/year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="0.02" upper_limit="0.06"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.03" upper_limit="0.08"/>
                    <measurement group_id="O3" value="0.04" lower_limit="0.02" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.837</p_value>
            <method>negative binomial</method>
            <method_desc>Model includes treatment, region, any prior exacerbation resulting ER/Hospitalization, use of OCS</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>1.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.538</p_value>
            <method>negative binomial</method>
            <method_desc>Model includes treatment, region, any prior exacerbation resulting ER/Hospitalization, use of OCS</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>2.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Benralizumab</title>
        <description>Mean PK Concentration at each visit</description>
        <time_frame>Baseline, Week 4, Week 8, Week 16, Week 24, Week 32, Week 40, Week 48, Week 56, Week 60</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Benralizumab</title>
          <description>Mean PK Concentration at each visit</description>
          <population>PK analysis set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="424"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=435, 419)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Value is less than lower limit of quantification</measurement>
                    <measurement group_id="O2" value="NA">Value is less than lower limit of quantification</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=430, 416)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="650.04" spread="154.61"/>
                    <measurement group_id="O2" value="703.16" spread="89.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=414, 395)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="894.86" spread="148.91"/>
                    <measurement group_id="O2" value="939.45" spread="98.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=390, 378)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="936.43" spread="247.46"/>
                    <measurement group_id="O2" value="252.54" spread="274.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=388, 361)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="827.09" spread="370.64"/>
                    <measurement group_id="O2" value="188.99" spread="308.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=345, 323)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="823.21" spread="362.43"/>
                    <measurement group_id="O2" value="166.53" spread="289.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=370, 338)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="859.69" spread="364.28"/>
                    <measurement group_id="O2" value="172.28" spread="298.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=355, 337)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="888.09" spread="333.98"/>
                    <measurement group_id="O2" value="186.5" spread="290.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56 (n=358, 344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="763.98" spread="309.18"/>
                    <measurement group_id="O2" value="173.41" spread="235.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (n=49, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.63" spread="1782.96"/>
                    <measurement group_id="O2" value="18.63" spread="756.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity of Benralizumab</title>
        <description>Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at &gt;=2 post-baseline assessments (with &gt;=16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive is defined as having at least one post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.</description>
        <time_frame>Pre-treatment until end of follow-up</time_frame>
        <population>Safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity of Benralizumab</title>
          <description>Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at &gt;=2 post-baseline assessments (with &gt;=16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive is defined as having at least one post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.</description>
          <population>Safety analysis set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="438"/>
                <count group_id="O2" value="427"/>
                <count group_id="O3" value="440"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive at any visit (n=438, 427, 440)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Base- and Post-baseline Postive (n=431, 414, 430)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Only post-baseline positive (n=431, 420, 436)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistently positive (n=431, 420, 436)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transient positive (n=431, 420, 436)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Only baseline positive (n=438, 421, 434)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extent of Exposure</title>
        <description>Extent of exposure is defined as the duration of treatment in days</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 56</time_frame>
        <population>Safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Extent of Exposure</title>
          <description>Extent of exposure is defined as the duration of treatment in days</description>
          <population>Safety analysis set</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="438"/>
                <count group_id="O2" value="428"/>
                <count group_id="O3" value="440"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="344.14" spread="73.129"/>
                    <measurement group_id="O2" value="331.64" spread="88.839"/>
                    <measurement group_id="O3" value="336.69" spread="82.148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 56 in AQLQ(S)+12</title>
        <description>AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of &gt;=0.5 are considered clinically meaningful.</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 56</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 56 in AQLQ(S)+12</title>
          <description>AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of &gt;=0.5 are considered clinically meaningful.</description>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread="1.15"/>
                    <measurement group_id="O2" value="1.61" spread="1.24"/>
                    <measurement group_id="O3" value="1.32" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.119</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline AQLQ score, region, use of OCS, visit, visit by treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.04</ci_lower_limit>
            <ci_upper_limit>0.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline AQLQ score, region, use of OCS, visit, visit by treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>0.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 56 in EQ-5D-5L VAS</title>
        <description>EQ-5D-5L VAS is to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 56</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 56 in EQ-5D-5L VAS</title>
          <description>EQ-5D-5L VAS is to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.</description>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="179"/>
                <count group_id="O3" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="21.52"/>
                    <measurement group_id="O2" value="15.5" spread="20.36"/>
                    <measurement group_id="O3" value="12.1" spread="20.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Work Productivity Loss Due to Asthma</title>
        <description>WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked. This is only applicable to patients who were employed.</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 56</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS, who were employed</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Work Productivity Loss Due to Asthma</title>
          <description>WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked. This is only applicable to patients who were employed.</description>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS, who were employed</population>
          <units>Percent of productivity loss</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.56" spread="25.589"/>
                    <measurement group_id="O2" value="24.44" spread="24.689"/>
                    <measurement group_id="O3" value="27.29" spread="25.802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Productivity Loss Due to Asthma in Classroom</title>
        <description>WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Classroom productivity loss is derived by sum of percentage of missed classes due to asthma and product of percentage of actual hours attending classes times degree of asthma affecting classroom productivity. Percentage of missed classes due to asthma is calculated by number of hours missed classes due to asthma divided by total number of hours missed classes plus number of hours actually attending classes. This is only applicable for patients who took classes.</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 56</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS, who took classes</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Productivity Loss Due to Asthma in Classroom</title>
          <description>WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Classroom productivity loss is derived by sum of percentage of missed classes due to asthma and product of percentage of actual hours attending classes times degree of asthma affecting classroom productivity. Percentage of missed classes due to asthma is calculated by number of hours missed classes due to asthma divided by total number of hours missed classes plus number of hours actually attending classes. This is only applicable for patients who took classes.</description>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS, who took classes</population>
          <units>percent of productivity loss</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.92" spread="23.765"/>
                    <measurement group_id="O2" value="14" spread="16.733"/>
                    <measurement group_id="O3" value="33.5" spread="25.593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Utilized Health Care Resources</title>
        <time_frame>Immediately following the first administration of study drug through Study Week 56</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Utilized Health Care Resources</title>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hospitalizations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emergency department visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unscheduled outpatient visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Home visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Telephone calls</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ambulance transports</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient and Clinician Assessment of Response to Treatment</title>
        <description>CGIC (clinician global impression of change), and PGIC (patient global impression of change) are overall evaluation of response to treatment, conducted separately by investigator and patient using a 7-point rating scale, ranging from 1 (Very much Improved), to 7 (Very much Worse). This endpoint was added after the second protocol amendment, thus not all patients had data to be analyzed.</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 56</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Patient and Clinician Assessment of Response to Treatment</title>
          <description>CGIC (clinician global impression of change), and PGIC (patient global impression of change) are overall evaluation of response to treatment, conducted separately by investigator and patient using a 7-point rating scale, ranging from 1 (Very much Improved), to 7 (Very much Worse). This endpoint was added after the second protocol amendment, thus not all patients had data to be analyzed.</description>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL, High-dose ICS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CGIC, Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CGIC, Much Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CGIC, Very Much Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CGIC, Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                    <measurement group_id="O2" value="190"/>
                    <measurement group_id="O3" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGIC, Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGIC, Much Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGIC, Very Much Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGIC, Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="205"/>
                    <measurement group_id="O3" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Benralizumab 30 mg q.4 Weeks</title>
          <description>Benralizumab administered subcutaneously every 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Benralizumab 30 mg q.8 Weeks</title>
          <description>Benralizumab administered subcutaneously every 8 weeks</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo administered subcutaneously</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="428"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Bronchitis haemophilus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Pseudomonas bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anastomotic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Epiphysiolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Jaw cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="438"/>
                <counts group_id="E2" events="27" subjects_affected="19" subjects_at_risk="428"/>
                <counts group_id="E3" events="38" subjects_affected="23" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Nasal turbinate hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Parakeratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Urticaria papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="244" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="232" subjects_at_risk="428"/>
                <counts group_id="E3" subjects_affected="264" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="438"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="428"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="438"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="428"/>
                <counts group_id="E3" events="19" subjects_affected="14" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="51" subjects_affected="40" subjects_at_risk="438"/>
                <counts group_id="E2" events="54" subjects_affected="45" subjects_at_risk="428"/>
                <counts group_id="E3" events="72" subjects_affected="54" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="27" subjects_affected="24" subjects_at_risk="438"/>
                <counts group_id="E2" events="17" subjects_affected="12" subjects_at_risk="428"/>
                <counts group_id="E3" events="27" subjects_affected="25" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="132" subjects_affected="90" subjects_at_risk="438"/>
                <counts group_id="E2" events="131" subjects_affected="82" subjects_at_risk="428"/>
                <counts group_id="E3" events="147" subjects_affected="92" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="438"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="428"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="438"/>
                <counts group_id="E2" events="24" subjects_affected="18" subjects_at_risk="428"/>
                <counts group_id="E3" events="22" subjects_affected="17" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="31" subjects_affected="23" subjects_at_risk="438"/>
                <counts group_id="E2" events="30" subjects_affected="21" subjects_at_risk="428"/>
                <counts group_id="E3" events="56" subjects_affected="39" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="35" subjects_affected="29" subjects_at_risk="438"/>
                <counts group_id="E2" events="53" subjects_affected="37" subjects_at_risk="428"/>
                <counts group_id="E3" events="53" subjects_affected="42" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="438"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="428"/>
                <counts group_id="E3" events="14" subjects_affected="10" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="438"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="428"/>
                <counts group_id="E3" events="20" subjects_affected="16" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="63" subjects_affected="33" subjects_at_risk="438"/>
                <counts group_id="E2" events="65" subjects_affected="34" subjects_at_risk="428"/>
                <counts group_id="E3" events="57" subjects_affected="32" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="76" subjects_affected="50" subjects_at_risk="438"/>
                <counts group_id="E2" events="50" subjects_affected="32" subjects_at_risk="428"/>
                <counts group_id="E3" events="96" subjects_affected="52" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="438"/>
                <counts group_id="E2" events="18" subjects_affected="14" subjects_at_risk="428"/>
                <counts group_id="E3" events="12" subjects_affected="8" subjects_at_risk="440"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="438"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="428"/>
                <counts group_id="E3" events="28" subjects_affected="24" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="438"/>
                <counts group_id="E2" events="23" subjects_affected="18" subjects_at_risk="428"/>
                <counts group_id="E3" events="24" subjects_affected="22" subjects_at_risk="440"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>≥ 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ’s Confidential Information without AZ’s written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mitchell Goldman, Medical Science Director</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+1 301 398 0323</phone>
      <email>Mitchell.Goldman@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

